Study record

MOTS-c regulates the ROS/TXNIP/NLRP3 pathway to alleviate diabetic cardiomyopathy

Fu Y, Tang M, Duan Y et al. · Biochem Biophys Res Commun · 2024

AnimalMOTS-c administeredEvidence tier C

What this study reported

Reported that administered MOTS-c was associated with lower ROS/TXNIP/NLRP3 pathway protein expression and less myocardial inflammatory change in rats with diet- and streptozotocin-induced diabetes.

Limitations

Single rat strain, males only, with group sizes and blinding not reported; readouts are protein markers and histology rather than cardiac function measures.

Study record

Annotated fields for this study
Study modelAnimal study (in vivo)
Substance studiedMOTS-c administeredSynthetic MOTS-c was given to cells, animals or people.
Speciesrat
System studiedMale Sprague-Dawley rats with high-sugar-fat diet and streptozotocin-induced diabetes
PopulationNot reported
DesignControlled animal experiment
Sample size as reportedNot reported
Control groupdiabetic rats not given MOTS-c
Route (data field only)intraperitoneal
Endpoints measuredcardiac structure; reactive oxygen species; TXNIP; NLRP3 inflammasome proteins; myocardial inflammatory markers
Pathways measuredInflammation · Oxidative stress
Research areasCardiovascular · Metabolic
Evidence tierC — Animal in vivo
Publication typesJournal Article, Research Support, Non-U.S. Gov't

Appraisal

Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.

Relevance to MOTS-c
Direct
Model applicability
Mammalian
Sample size
Not reported
Controls
Appropriate
Outcome validity
Surrogate
Support for its own conclusion
Moderate

Provenance

  • Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
  • Annotated from the published abstract.
  • Editorial review: approved (2026-11-11).
  • Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.